This result suggests that although the modulation of CD6 with itolizumab activates cytotoxic lymphocytes, the enhancement of tumor cell killing with the antibody is dependent on the disruption of the CD318 inhibitory signal on CD8+ T cells and NK cells by blocking the CD6-CD318 interaction. Here, CD8A is linked to neoplasm.